Tags

Type your tag names separated by a space and hit enter

Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
J Obstet Gynaecol Res. 2011 Aug; 37(8):1084-91.JO

Abstract

AIM

To evaluate the urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine treatment for women with overactive bladder syndrome.

METHODS

Patients were randomized to receive either solifenacin 5 mg or tolterodine ER 4 mg once a day for 12 weeks at each four-week visit in a post-marketing study. Only women (solifenacin [n = 26] vs. tolterodine [n = 22]) were included in this subgroup analysis. Adverse events and changes of urodynamic values and clinical data were compared between the solifenacin and tolterodine groups.

RESULTS

The volume voided per micturition increased in the solifenacin group (n = 21) (P = 0.04). The strong desire to void and pad-test result improved in the tolterodine group (n = 21; P = 0.02 and 0.03, respectively). There were no between-group differences in changes of any urodynamic data, voiding diary values or adverse events after treatment; however, changes of heart rate differed between the two groups (P = 0.0004), especially at visit 2 (solifenacin vs. tolterodine, -4.3 vs. 3.8, P = 0.02) and visit 3 (-3.2 vs. 4.8, P = 0.03).

CONCLUSIONS

Both solifenacin and tolterodine had similar urodynamic effects, therapeutic efficacy and adverse events in treating women with overactive bladder syndrome; however, tolterodine had a greater effect in increasing heart rate than solifenacin.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Pan-Chiao, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase IV
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21501328

Citation

Hsiao, Sheng-Mou, et al. "Comparisons of Urodynamic Effects, Therapeutic Efficacy and Safety of Solifenacin Versus Tolterodine for Female Overactive Bladder Syndrome." The Journal of Obstetrics and Gynaecology Research, vol. 37, no. 8, 2011, pp. 1084-91.
Hsiao SM, Chang TC, Wu WY, et al. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res. 2011;37(8):1084-91.
Hsiao, S. M., Chang, T. C., Wu, W. Y., Chen, C. H., Yu, H. J., & Lin, H. H. (2011). Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. The Journal of Obstetrics and Gynaecology Research, 37(8), 1084-91. https://doi.org/10.1111/j.1447-0756.2010.01493.x
Hsiao SM, et al. Comparisons of Urodynamic Effects, Therapeutic Efficacy and Safety of Solifenacin Versus Tolterodine for Female Overactive Bladder Syndrome. J Obstet Gynaecol Res. 2011;37(8):1084-91. PubMed PMID: 21501328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. AU - Hsiao,Sheng-Mou, AU - Chang,Ting-Chen, AU - Wu,Wen-Yih, AU - Chen,Chi-Hau, AU - Yu,Hung-Jeng, AU - Lin,Ho-Hsiung, Y1 - 2011/04/19/ PY - 2011/4/20/entrez PY - 2011/4/20/pubmed PY - 2012/1/21/medline SP - 1084 EP - 91 JF - The journal of obstetrics and gynaecology research JO - J. Obstet. Gynaecol. Res. VL - 37 IS - 8 N2 - AIM: To evaluate the urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine treatment for women with overactive bladder syndrome. METHODS: Patients were randomized to receive either solifenacin 5 mg or tolterodine ER 4 mg once a day for 12 weeks at each four-week visit in a post-marketing study. Only women (solifenacin [n = 26] vs. tolterodine [n = 22]) were included in this subgroup analysis. Adverse events and changes of urodynamic values and clinical data were compared between the solifenacin and tolterodine groups. RESULTS: The volume voided per micturition increased in the solifenacin group (n = 21) (P = 0.04). The strong desire to void and pad-test result improved in the tolterodine group (n = 21; P = 0.02 and 0.03, respectively). There were no between-group differences in changes of any urodynamic data, voiding diary values or adverse events after treatment; however, changes of heart rate differed between the two groups (P = 0.0004), especially at visit 2 (solifenacin vs. tolterodine, -4.3 vs. 3.8, P = 0.02) and visit 3 (-3.2 vs. 4.8, P = 0.03). CONCLUSIONS: Both solifenacin and tolterodine had similar urodynamic effects, therapeutic efficacy and adverse events in treating women with overactive bladder syndrome; however, tolterodine had a greater effect in increasing heart rate than solifenacin. SN - 1447-0756 UR - https://www.unboundmedicine.com/medline/citation/21501328/Comparisons_of_urodynamic_effects_therapeutic_efficacy_and_safety_of_solifenacin_versus_tolterodine_for_female_overactive_bladder_syndrome_ L2 - https://doi.org/10.1111/j.1447-0756.2010.01493.x DB - PRIME DP - Unbound Medicine ER -